AU2018298087A1 - Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis - Google Patents

Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis Download PDF

Info

Publication number
AU2018298087A1
AU2018298087A1 AU2018298087A AU2018298087A AU2018298087A1 AU 2018298087 A1 AU2018298087 A1 AU 2018298087A1 AU 2018298087 A AU2018298087 A AU 2018298087A AU 2018298087 A AU2018298087 A AU 2018298087A AU 2018298087 A1 AU2018298087 A1 AU 2018298087A1
Authority
AU
Australia
Prior art keywords
carcinoma
cancer
lactis
mage
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018298087A
Other languages
English (en)
Inventor
William CAFFREY
Anupriya Dutta
Humphrey Gardner
Brian Goodman
Jacqueline PAPKOFF
Holly PONICHTERA
Peter SANDY
Maria Sizova
Hank WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evelo Biosciences Inc
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63036353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018298087(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AU2018298087A1 publication Critical patent/AU2018298087A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018298087A 2017-07-05 2018-07-05 Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis Abandoned AU2018298087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762528669P 2017-07-05 2017-07-05
US62/528,669 2017-07-05
PCT/US2018/040841 WO2019010255A1 (en) 2017-07-05 2018-07-05 COMPOSITIONS AND METHODS FOR TREATING CANCER USING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS

Publications (1)

Publication Number Publication Date
AU2018298087A1 true AU2018298087A1 (en) 2020-01-23

Family

ID=63036353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018298087A Abandoned AU2018298087A1 (en) 2017-07-05 2018-07-05 Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis

Country Status (12)

Country Link
US (3) US10792314B2 (cg-RX-API-DMAC7.html)
EP (1) EP3648780A1 (cg-RX-API-DMAC7.html)
JP (1) JP7254786B2 (cg-RX-API-DMAC7.html)
KR (1) KR102563191B1 (cg-RX-API-DMAC7.html)
CN (1) CN111356464A (cg-RX-API-DMAC7.html)
AR (1) AR112328A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018298087A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019028301A2 (cg-RX-API-DMAC7.html)
CA (1) CA3068757A1 (cg-RX-API-DMAC7.html)
MA (1) MA51770A (cg-RX-API-DMAC7.html)
TW (1) TW201906620A (cg-RX-API-DMAC7.html)
WO (1) WO2019010255A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
HK1253064A1 (zh) * 2015-06-01 2019-06-06 The University Of Chicago 通过操纵共生微生物菌群对癌症的治疗
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
CN112566648A (zh) 2018-07-16 2021-03-26 4D制药研究有限公司 包含细菌菌株的组合物
AU2019396657A1 (en) 2018-12-12 2021-07-08 4D Pharma Research Limited Compositions comprising Parabacteroides bacterial strains for treating cancer
JP2022537684A (ja) * 2019-06-11 2022-08-29 エヴェロ バイオサイエンシズ,インコーポレーテッド 分泌された微生物細胞外小胞
WO2021022110A1 (en) 2019-08-01 2021-02-04 Evelo Biosciences, Inc. Inducing immune effects using bacteria of the genus bifidobacterium
KR102357904B1 (ko) * 2019-10-29 2022-02-04 경희대학교 산학협력단 항암용 금 나노입자
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用
WO2022164870A1 (en) * 2021-01-26 2022-08-04 Cb Therapeutics, Inc. Recombinant polyprenol diphosphate synthases
TW202304415A (zh) * 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
CN113368259B (zh) * 2021-06-22 2022-07-22 海南大学 一种基于修饰细菌加载纳米药物的方法及其复合物和在治疗结肠癌中的应用
US20230096810A1 (en) * 2021-09-24 2023-03-30 Johnson & Johnson Consumer Inc. Dosage forms for the delivery of a probiotic
CN114028432A (zh) * 2021-11-05 2022-02-11 上海市第十人民医院 双歧杆菌提升铂类化疗药物敏感性的药物新用途
CN115363094A (zh) * 2021-11-30 2022-11-22 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用
CN114480229B (zh) * 2022-04-15 2022-08-09 微康益生菌(苏州)股份有限公司 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用
CN115216423B (zh) * 2022-06-15 2023-04-25 南昌大学 一种动物双歧杆菌sf及其在医药和食品中的应用
WO2025071560A1 (en) * 2023-09-28 2025-04-03 Rutgers, The State University Of New Jersey Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof
CN117417866B (zh) * 2023-10-27 2026-02-27 江南大学 一种产胆盐水解酶的动物双歧杆菌及其在新生儿黄疸中的应用
CN117327632B (zh) * 2023-12-01 2024-02-13 四川厌氧生物科技有限责任公司 一种动物双歧杆菌及其应用
CN121046519B (zh) * 2025-11-05 2026-03-20 中国食品发酵工业研究院有限公司 动物双歧杆菌乳亚种bl-99的活菌定量检测方法及其引物、探针、试剂盒与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1481681A1 (en) 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
EP2046352A4 (en) 2006-06-06 2012-03-21 Univ Mcgill Fermented milk product and use thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
US8557233B2 (en) 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
EP1997907A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobacteria
US20110027348A1 (en) 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
EP2203551B1 (en) 2007-10-20 2013-08-21 Université de Liège Bifidobacterial species
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
PL2498789T3 (pl) 2009-11-11 2017-01-31 Alimentary Health Limited Probiotyczny szczep bifidobacterium
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP3033091B1 (en) 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma
US10203329B2 (en) 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
EP3139940B1 (en) * 2014-05-05 2021-02-17 Probiotical S.p.A. Composition comprising l. reuteri ler03 and l. salivarius ls06 for use in the treatment of tumors, aids and leukemias
CN104224851B (zh) 2014-08-15 2018-08-24 中国农业大学 动物双歧杆菌乳酸亚种CGMCC No.9273的应用
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
SG10201907660YA (en) 2015-01-23 2019-10-30 Univ Temple Use of short chain fatty acids in cancer prevention
EP3285777B1 (en) 2015-04-23 2021-06-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
SG11201708635QA (en) 2015-04-23 2017-11-29 Kaleido Biosciences Inc Microbiome regulators and related uses thereof
HK1253064A1 (zh) 2015-06-01 2019-06-06 The University Of Chicago 通过操纵共生微生物菌群对癌症的治疗
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
CN106110322A (zh) * 2016-07-29 2016-11-16 安徽瀚海博兴生物技术有限公司 一种药物组合物及其在制备治疗癌症药物中的应用
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법

Also Published As

Publication number Publication date
TW201906620A (zh) 2019-02-16
US10576111B2 (en) 2020-03-03
AR112328A1 (es) 2019-10-16
US20190224253A1 (en) 2019-07-25
CA3068757A1 (en) 2019-01-10
JP7254786B2 (ja) 2023-04-10
KR20200024911A (ko) 2020-03-09
US20190192585A1 (en) 2019-06-27
MA51770A (fr) 2020-05-13
KR102563191B1 (ko) 2023-08-02
EP3648780A1 (en) 2020-05-13
US10792314B2 (en) 2020-10-06
BR112019028301A2 (pt) 2020-07-14
JP2020526581A (ja) 2020-08-31
CN111356464A (zh) 2020-06-30
US20210093680A1 (en) 2021-04-01
WO2019010255A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
US10576111B2 (en) Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097
US10702561B2 (en) Pharmaceutical compositions comprising a Blautia strain
US11090341B2 (en) Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
US20190314427A1 (en) Methods of treating cancer using parabacteroides
US20210113628A1 (en) Intracellular delivery of biomolecules to modify immune response
WO2018112365A2 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
EP3746121A1 (en) Compositions and methods for treating immune disorders using lachnospiraceae bacteria
EP3982987A1 (en) Processed microbial extracellular vesicles
US11241461B2 (en) Treating cancer using a blautia strain
WO2021022110A1 (en) Inducing immune effects using bacteria of the genus bifidobacterium
WO2019178494A1 (en) Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
WO2019178490A1 (en) Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
WO2019178487A2 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
WO2019178055A1 (en) Extracellular vesicles from burkholderia
WO2019169160A1 (en) Compositions and methods for treating cancer using ruminococcus gnavus
WO2019169168A1 (en) Compositions and methods for treating cancer using agathobaculum
WO2019169181A1 (en) Compositions and methods for treating cancer using lactobacillus salivarius
WO2019169138A1 (en) Compositions and methods for treating cancer using paraclostridium benzoelyticum
WO2019169143A1 (en) Compositions and methods for treating cancer using turicibacter sanguinis
WO2020006216A1 (en) Compositions and methods of treating cancer using neisseria bacteria
WO2019178057A1 (en) Methods of treating cancer using burkholderia

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application